1. People's Republic of China Stocks

  2. •

    Financial Services

  3. •

    Insurance - Life
Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

000627.SZ
Hubei Biocause Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
1.58
CNY
+0.02
- -
7.75BMarket Cap
Hubei Biocause Pharmaceutical Co., Ltd.
000627.SZ
(Shenzhen Stock Exchange)

Recent

price

1.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
0.72
0.71
0.94
0.84
0.59
0.72
0.58
0.4
4.2
12.02
6.27
10.14
8.77
10.45
10.79
9.89
8.52
Revenue per Share
0.01
0.04
0.02
-0.08
0.01
-0.08
0.06
0.18
0.44
0.3
0.27
0.36
0.12
0.1
0.06
-0.13
-0.16
Basic EPS, GAAP
-0.3
-0.21
0.1
-0.06
-0.03
-0.01
-0.22
-0.06
-1.49
-0.08
2.99
5.65
4.37
0.83
1.62
1.89
-0.01
Free Cash Flow per Basic Share
0.04
0.01
0.03
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.06
0.05
0.13
0.08
0.15
0.28
0.15
Dividend per Share
0.61
0.6
1.02
0.94
0.98
0.92
0.94
1.12
1.53
1.83
1.87
2.18
2.24
2.39
2.51
2.04
2.01
Book Value per Share
0.95
0.89
0.88
0.76
0.88
0.78
0.71
0.94
3.38
4.52
3.99
5.69
5.83
6.59
6.15
5.42
5.98
Tangible Book Value per Share
1,255
1,359
1,349
1,356
1,314
1,347
1,397
1,374
4,043
4,421
4,913
4,933
4,836
4,707
4,568
5,014
4,938
Basic Weighted Avg Shares
909
965
1,261
1,134
780
968
806
556
16,989
53,152
30,805
50,042
42,433
49,175
49,264
49,593
42,082
Sales/Revenue/Turnover
1.67
4.73
0.59
-5.14
-4.79
-8.6
-11.68
-10.16
50.47
46.12
86.35
22.68
8.43
64.74
62.92
43.78
17.06
Operating Margin (%)
40
52
66
63
52
69
74
65
139
123
93
79
64
134
147
152
- -
Depreciation Expense
8
50
28
-102
12
-101
84
247
1,779
1,326
1,327
1,776
580
471
274
-652
-772
Net Income, GAAP
- -
6.61
6.36
- -
7.94
- -
22.79
25.09
9.43
1.69
9.83
19.68
22.87
- -
- -
- -
56.66
Effective Tax Rate (%)
0.9
5.21
2.25
-8.97
1.52
-10.44
10.39
44.48
10.47
2.5
4.31
3.55
1.37
0.96
0.56
-1.31
-1.83
Profit Margin (%)
463
279
271
235
35
-266
-184
-134
15,925
17,107
23,307
17,351
43,727
37,299
30,992
26,204
17,751
Working Capital
160
225
123
123
23
- -
- -
42
360
40
110
- -
2,830
6,204
6,878
7,171
5,579
LT Debt
1,513
1,574
1,602
1,414
1,537
1,418
1,490
1,784
20,398
26,705
26,015
34,353
34,588
37,475
34,603
33,634
36,005
Total Equity
- -
2.15
0.35
- -
-1.86
- -
-3.86
-2.11
63.87
85.02
73.15
25.38
6.66
- -
- -
- -
- -
Return on Invested Capital (%)
- -
5.22
3.34
- -
2.1
- -
6.01
14.13
5.44
-0.14
1.25
-43.38
-0.42
- -
- -
- -
-0.08
Return on Capital (%)
1.11
6.37
2.6
-7.69
0.93
-8.02
6.57
17.32
46.08
18.59
15.36
17.8
5.37
4.26
2.41
-6.01
-7.49
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
16,588
10,930
11,976
LT Borrowings
7,206
5,510
5,510
LT Finance Leases
54
59
69
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,941
4,941
4,941
Market Capitalization
12,198
8,642
18,321

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
44,632
35,297
35,199
Cash, Cash Equivalents & STI
23,028
13,487
10,570
Accounts Receivable, Net
103
107
99
Inventories
4,295
4,357
3,871
Total Current Liabilities
23,537
17,082
17,448
Payables & Accruals
- -
- -
- -
ST Debt
16,588
10,930
11,976
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
112.73%
6.12%
-2.8%
Free Cash Flow
459.65%
20.4%
28.12%
Net Income, GAAP
17.4%
-86.38%
-337.82%
Sales/Revenue/Turnover
314.34%
12.8%
0.67%
Total Cash Common Dividend
77.99%
57.03%
102.03%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
18,131
9,206
10,169
11,758
49,264
2023
21,902
11,456
7,684
8,551
49,593
2024
17,460
11,559
4,512
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
0.03
- -
- -
- -
0.06
2023
0.01
- -
- -
- -
-0.13
2024
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
0.02
- -
- -
- -
0.15
2023
0.03
- -
- -
- -
0.28
2024
0.03
- -
- -
- -
- -
Similar Companies
China Life Insurance Company Limited (601628.SS)
Great-West Lifeco Inc. (0AH3.L)
Yunfeng Financial Group Limited (0376.HK)
Great-West Lifeco Inc. (GWO-PI.TO)
Chesnara plc (CSN.L)
Standard Life plc (SDLF.L)
Business
Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) is a China-based diversified company principally engaged in providing life insurance, health insurance, and casualty insurance products; manufacturing and exporting active pharmaceutical ingredients (APIs), pharmaceutical preparations, and chemicals; and operating in new energy fuels. The company manufactures APIs including Ibuprofen, D-Ibuprofen (Dexibuprofen), Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate, Flumazenil, Homatropine Hydrobromide, Hyoscyamine Sulfate, and others; pharmaceutical formulations such as Ibuprofen Granules, Ibuprofen Tablets, and Torasemide Tablets; and chemicals comprising dimethyl ether gas and alpha-chloropropionyl chloride. Its products target therapeutic areas including non-steroidal anti-inflammatory drugs, cardiovascular and cerebrovascular treatments, and anti-tumor medications, with exports to approximately 85 countries, including the United States, the European Union, and other regulated international markets. Founded in 1993 and headquartered at No. 122 Yangwan Road, Jingmen, Hubei Province, China, the company operates primarily in China across pharmaceuticals, insurance, chemicals, and energy sectors, serving healthcare providers, insurers, and industrial customers. In recent strategic developments, Hubei Biocause authorized a CNY 100 million share buyback plan on June 14, 2024, repurchasing 36.49 million shares (0.74% of total shares) by April 30, 2025 to enhance shareholder value; its insurance subsidiary Guohua Life Insurance reported CNY 31.4 billion in original insurance premium income for January through October 2024; and the company faced significant operational challenges, including stock trading suspension since May 6, 2025 due to delayed disclosure of 2024 annual and 2025 first-quarter reports, culminating in delisting from the Shenzhen Stock Exchange on September 30, 2025.